

Mats Jerkeman
Lymfom - Klinisk forskning
LUCC: Lunds universitets cancercentrum
Medicinsk onkologi
Adressotyp: Postadress.
Lunds Universitet, Box 117
221 00
Sverige
Adressotyp: Postadress.
Universitetssjukhuset, SUS
221 85
Lund
Sverige
E-post: mats.jerkeman@med.lu.se
Mobil: +46704973507
Telefon: +4646177827



Forskning

Maligna lymfom är tumörer utgående från immunsystemet. De innefattar ca 50 olika undergrupper med vitt skilda kliniska förlopp. Vår grupp har sedan många år bedrivit forskning angående kring samtliga aspekter av lymfom: studier av tumöriogenetiken med immunhistokemiska och molekylärbiologiska metoder, utveckling av diagnostik, samt populationsbaserade studier utgående från det Svenska Lymfomregistret. Unikt i Sverige är att vi också kunnat initiera egna kliniska prövningar med nya läkemedel för lymfombehandling.

Anställning

Projektledare

Lymfom - Klinisk forskning
Lunds universitet
Sverige
2016 okt. 13 → present

Principal Investigator

LUCC: Lunds universitets cancercentrum
Lunds universitet
Sverige
2020 feb. 10 → present

Handledare, Avdelningschef, Professor

Medicinsk onkologi
Lunds universitet
Lund, Sverige
2020 maj 4 → present

Editor, ESMO Guidelines

European Society of Medical Oncology (ESMO)
Schweiz
2019 jan. 1 → present

Ordförande

Swedish Lymphoma Group
Sverige
2014 jan. 14 → present

Forskningsoutput

Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma

Lindberg, Å., Johansson, Å., Kahn, F., Jönsson, G. & Jerkeman, M., 2025 jan., I: Hematological Oncology. 43, 1, e70014.

Limited stage mantle cell lymphoma: A real-world study of primary treatment and prognosis in Sweden 2006–2018

Albertsson-Lindblad, A., Ekberg, S., Glimelius, I., Ellin, F., Sonnevi, K., Lewerin, C., Brandefors, L., Smedby, K. E. & Jerkeman, M., 2025 jan., I: HemaSphere. 9, 1, e70080.

Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older

Pahnke, S., Abalo, K. D., Ekberg, S., Albertsson-Lindblad, A., E. Smedby, K., Jerkeman, M. & Glimelius, I., 2024 dec., I: Blood Cancer Journal. 14, 1, 222.

Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia: a randomized controlled trial

Mekuria, S. F., Biazin, H., Abebe, T., Borgfeldt, C., Assegid, N., Mihret, A., Nemomsa, R. O., Forslund, O. & Jerkeman, M., 2024 nov. 4, I: International Journal of Gynecological Cancer. 34, 11, s. 1691-1697 7 s.

Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study

Rask Kragh Jørgensen, R., Jakobsen, L. H., Eloranta, S., Smedby, K. E., Pedersen, R. S., Jørgensen, J. M., Clausen, M. R., Brown, P., Gang, A. O., Gade, I. L., Larsen, T. S., Jerkeman, M. & El-Galaly, T. C., 2024 nov., I: European Journal of Haematology. 113, 5, s. 641-650 10 s.

Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: the Obesity and Disease Development Sweden (ODDS) pooled cohort study

Sun, M., da Silva, M., Bjørge, T., Fritz, J., Mboya, I. B., Jerkeman, M., Stattin, P., Wahlström, J., Michaëllsson, K., van Guelpen, B., Magnusson, P. K. E., Sandin, S., Yin, W., Lagerros, Y. T., Ye, W., Nwaru, B., Kankaanranta, H., Lönnberg, L., Chabok, A. & Isaksson, K. och 6 andra, Pedersen, N. L., Elmståhl, S., Lind, L., Hedman, L., Häggström, C. & Stocks, T., 2024 okt., I: The Lancet regional health. Europe. 45, 101034.

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia*

Eichhorst, B., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Hallek, M., Jerkeman, M., Buske, C. & ESMO Guidelines Committee, 2024 sep., I: Annals of Oncology. 35, 9, s. 762-768 7 s.

CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression

de Matos Rodrigues, J., Lokhande, L., Olsson, L. M., Hassan, M., Johansson, A., Janská, A., Kumar, D., Schmidt, L., Nikkarinen, A., Hollander, P., Glimelius, I., Porwit, A., Gerdts, A. S., Jerkeman, M. & Ek, S., 2024 aug. 27, I: Blood Advances. 8, 16, s. 4370-4385 16 s.

Infections in patients with mantle cell lymphoma

Abalo, K. D., Ekberg, S., Andersson, T. M. L., Pahnke, S., Albertsson-Lindblad, A., Smedby, K. E., Jerkeman, M. & Glimelius, I., 2024 juli, I: HemaSphere. 8, 7, e121.

Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients

Lokhande, L., Nilsson, D., de Matos Rodrigues, J., Hassan, M., Olsson, L. M., Pyl, P.-T., Vasquez, L., Porwit, A., Gerdts, A. S., Jerkeman, M. & Ek, S., 2024 juni 21, I: Cancers. 16, 13

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up*

Ferreri, A. J. M., Illerhaus, G., Doorduijn, J. K., Auer, D. P., Bromberg, J. E. C., Calimeri, T., Cwynarski, K., Fox, C. P., Hoang-Xuan, K., Malaise, D., Ponzoni, M., Schorb, E., Soussain, C., Specht, L., Zucca, E., Buske, C., Jerkeman, M., Dreyling, M., EHA Guidelines Committee & ESMO Guidelines Committee, 2024 juni, I: Annals of Oncology. 35, 6, s. 491-507 17 s.

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

EHA Guidelines Committee & ESMO Guidelines Committee, 2024 juni, I: HemaSphere. 8, 6, e89.

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Dreyling, M., Doorduijn, J., Giné, E., Jerkeman, M., Walewski, J., Hutchings, M., Mey, U., Riise, J., Trneny, M., Vergote, V., Shpilberg, O., Gomes da Silva, M., Leppä, S., Jiang, L., Stilgenbauer, S., Kerkhoff, A., Jachimowicz, R. D., Celli, M., Hess, G. & Arcaini, L. och 18 andra, Visco, C., van Meerten, T., Wirths, S., Zinzani, P. L., Novak, U., Herhaus, P., Benedetti, F., Sonnevi, K., Hanoun, C., Hänel, M., Dierlamm, J., Pott, C., Klapper, W., Gözel, D., Schmidt, C., Unterhalt, M., Ladetto, M. & Hoster, E., 2024 maj 25, I: The Lancet. 403, 10441, s. 2293-2306 14 s.

Tattoos as a risk factor for malignant lymphoma: a population-based case-control study

Nielsen, C., Jerkeman, M. & Jöud, A., 2024 maj 21, I: EClinicalMedicine. 72, 102649.

MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study

Rodrigues, J. M., Hollander, P., Schmidt, L., Gkika, E., Razmara, M., Kumar, D., Geisler, C., Grønbæk, K., Eskelund, C. W., Räty, R., Kolstad, A., Sundström, C., Glimelius, I., Porwit, A., Jerkeman, M. & Ek, S., 2024 apr., I: Haematologica. 109, 4, s. 1171-1183 13 s.

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial

Jerkeman, M., Kolstad, A., Hutchings, M., Pasanen, A., Meriranta, L., Niemann, C. U., Jørgensen, R. R. K., El-Galaly, T. C., Riise, J., Leppä, S., Christensen, J. H., Sonnevi, K., Pedersen, L. B., Wader, K. F. & Glimelius, I., 2024 jan. 23, I: Blood Advances. 8, 2, s. 407-415 9 s.

ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia

Hoelzer, D., Bassan, R., Boissel, N., Roddie, C., Ribera, J. M., Jerkeman, M. & ESMO Guidelines Committee, 2024 jan., I: Annals of Oncology. 35, 1, s. 15-28 14 s.

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, P. L., Linton, K., Vilmar, A., Jerkeman, M., Chen, J. M. H., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, V. R., Sancho, J. M., Jimenez-Ubieto, A., Fischer, L., Eyre, T. A., Keeping, S. & Park, J. E. och 5 andra, Wu, J. J., Nunes, A., Reitan, J., Wade, S. W. & Salles, G., 2024, I: Leukemia and Lymphoma. 65, 1, s. 14-25 12 s.

Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas

Arffman, M., Meriranta, L., Autio, M., Holte, H., Jørgensen, J. M., Brown, P., Jyrkkiö, S., Jerkeman, M., Drott, K., Fluge, Ø., Björkholm, M., Lindsberg, M. L. K., Beiske, K., Pedersen, M., Leivonen, S.-K. & Leppa, S., 2024, I: Med (New York, N.Y.). 5, 6, s. 583-602.e5

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Martelli, M., Jerkeman, M., Zucca, E. & International Extranodal Lymphoma Study Group (IELSG), 2024, I: Journal of Clinical Oncology. 42, 34, s. 4071-4083 13 s.

Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

Harrysson, S., Eloranta, S., Ekberg, S., Enblad, G., Andersson, P. O., Sonnevi, K., Ljungqvist, M., Sander, B., Jerkeman, M. & Smedby, K. E., 2024, I: Leukemia and Lymphoma. 65, 4, s. 534-537 4 s.

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Bhansali, R. S., Relander, T., Jerkeman, M., Barta, S. K. & et al., 2024, I: Blood Advances. 8, 13, s. 3507-3518 12 s.

The National Swedish Lymphoma Register – a systematic validation of data quality

Smedby, K. E., Eloranta, S., Wästerlid, T., Falini, V., Jerlström, U., Ellin, F., Papworth, K., Westerberg, J., Lewerin, C., Andersson, P. O., Kristjansdottir, H. L., Brandefors, L., Mörth, C., Hallén, K., Kuric, N., Sabaa, A. A., Wahlin, B. E., Molin, D., Enblad, G. & Hörstedt, A. S. och 2 andra, Jerkeman, M. & Glimelius, I., 2024, I: *Acta Oncologica*. 63, s. 563-572 10 s.

Secondary malignancies among mantle cell lymphoma patients

Abalo, K. D., Smedby, K. E., Ekberg, S., Eloranta, S., Pahnke, S., Albertsson-Lindblad, A., Jerkeman, M. & Glimelius, I., 2023 dec., I: *European Journal of Cancer*. 195, 113403.

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma

Nikkarinen, A., Lokhande, L., Amini, R. M., Jerkeman, M., Porwit, A., Molin, D., Enblad, G., Kolstad, A., Räty, R., Hutchings, M., Weibull, C. E., Hollander, P., Ek, S. & Glimelius, I., 2023 sep. 26, I: *Blood Advances*. 7, 18, s. 5304-5313 10 s.

Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCL complete Project

Jerkeman, M., Ekberg, S., Glimelius, I., Albertsson-Lindblad, A., Entrop, J. P., Ellin, F., Sonnevi, K., Lewerin, C., Brandefors, L. & Smedby, K. E., 2023 aug., I: *HemaSphere*. 7, 8, s. E928

Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation

Ekberg, S., Smedby, K. E., Albertsson-Lindblad, A., Jerkeman, M., Weibull, C. E. & Glimelius, I., 2023 mars 14, I: *Blood Advances*. 7, 5, s. 866-874 9 s.

Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma

Adam, M., Bekuretsion, Y., Gebremedhin, A., Kwiecinska, A., Howe, R., Petros, B. & Jerkeman, M., 2023, I: *Journal of Clinical and Experimental Hematopathology*. 63, 4, s. 230-239 10 s.

Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score

Salim, R., Husby, S., Winther Eskelund, C., Scott, D. W., Holte, H., Kolstad, A., Räty, R., Ek, S., Jerkeman, M., Geisler, C., Sommer Kristensen, L., Dahl, M. & Grønbæk, K., 2023, I: *Leukemia and Lymphoma*. 64, 8, s. 1414-1423 10 s.

HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC: a systematic review and meta-analysis

Mekuria, S. F., Timmermans, S., Borgfeldt, C., Jerkeman, M., Johansson, P. & Linde, D. S., 2023, I: *Systematic Reviews*. 12, 1, 103.

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors

Sandström Gerdsson, A., de Matos Rodrigues, J., Eskelund, C. W., Husby, S., Gronbaek, K., Räty, R., Kolstad, A., Geisler, C. H., Porwit, A., Jerkeman, M. & Ek, S., 2023, I: *Haematologica*. 108, 4, s. 1092-1104

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, P. L., Linton, K., Vilmar, A., Jerkeman, M., Chen, J. M. H., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, V. R., Sancho, J. M., Ubieto, A. J., Fischer, L., Eyre, T. A., Keeping, S. & Park, J. E. och 5 andra, Wu, J. J., Siddiqi, R., Reitan, J., Wade, S. & Salles, G., 2023, I: *British Journal of Haematology*. 202, 4, s. 749-759

Tackling Mantle Cell Lymphoma in Europe

Horgan, D., Walewski, J., Aurer, I., Visco, C., Giné, E., Fetica, B., Jerkeman, M., Kozaric, M., da Silva, M. G. & Dreyling, M., 2022 sep., I: *Healthcare (Switzerland)*. 10, 9, 1682.

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

Wang, M. L., Jurczak, W., Jerkeman, M., Trotman, J., Zinzani, P. L., Belada, D., Boccomini, C., Flinn, I. W., Giri, P., Goy, A., Hamlin, P. A., Hermine, O., Hernández-Rivas, J. Á., Hong, X., Kim, S. J., Lewis, D., Mishima, Y., Özcan, M., Perini, G. F. & Pocock, C. och 12 andra, Song, Y., Spurgeon, S. E., Storrington, J. M., Walewski, J., Zhu, J., Qin, R., Henninger, T., Deshpande, S., Howes, A., Le Gouill, S., Dreyling, M. & the SHINE Investigators, 2022 juni 30, I: *New England Journal of*

Medicine. 386, 26, s. 2482-2494 13 s.

Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients

Mead, M., Cederleuf, H., Bjorklund, M., Wang, X., Relander, T., Jerkeman, M., Gaut, D., Larson, S. & Ellin, F., 2022 apr. 12, I: Blood Advances. 6, 7, s. 2120-2128 9 s.

High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis

Kolijn, P. M., Hosnijeh, F. S., Späth, F., Hengeveld, P. J., Agathangelidis, A., Saleh, M., Casabonne, D., Benavente, Y., Jerkeman, M., Agudo, A., Barricarte, A., Besson, C., Sánchez, M. J., Chirlaque, M. D., Masala, G., Sacerdote, C., Grioni, S., Schulze, M. B., Nieters, A. & Engelfriet, P. och 4 andra, Hultdin, M., McKay, J. D., Vermeulen, R. C. H. & Langerak, A. W., 2022 mars 10, I: Blood. 139, 10, s. 1557-1563 7 s.

Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma

Meriranta, L., Alkodsi, A., Pasanen, A., Lepistö, M., Mapar, P., Blaker, Y. N., Jørgensen, J., Karjalainen-Lindsberg, M. L., Fiskvik, I., Mikalsen, L. T. G., Autio, M., Björkholm, M., Jerkeman, M., Fluge, Ø., Brown, P., Jyrkkö, S., Holte, H., Pitkänen, E., Ellonen, P. & Leppä, S., 2022 mars, I: Blood. 139, 12, s. 1863-1877 15 s.

Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

Fjordén, K., Ekberg, S., Kuric, N., Smedby, K. E., Lagerlöf, I., Larsen, T. S., Jørgensen, J. M., de Nully Brown, P. & Jerkeman, M., 2022 jan., I: British Journal of Haematology. 196, 2, s. 437-440 4 s.

Advances in immune therapies in hematological malignancies

Mazzarella, L., Enblad, G., Olweus, J., Malmberg, K. J. & Jerkeman, M., 2022, I: Journal of Internal Medicine. 292, 2 , s. 205-220

Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma

Merrien, M., Wasik, A. M., Ljung, E., Morsy, M. H. A., de Matos Rodrigues, J., Carlsten, M., Rassidakis, G. Z., Christensson, B., Kolstad, A., Jerkeman, M., Ek, S., Herold, N., Wahlin, B. E. & Sander, B., 2022, I: Virchows Archiv. 480, 3, s. 655-666

Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials

Dahl, M., Husby, S., Eskelund, C. W., Besenbacher, S., Fjelstrup, S., Côme, C., Ek, S., Kolstad, A., Räty, R., Jerkeman, M., Geisler, C. H., Kjems, J., Kristensen, L. S. & Grønbæk, K., 2022, I: Leukemia. 36, 1, s. 177-188

Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients

Harrysson, S., Eloranta, S., Ekberg, S., Enblad, G., El-Galaly, T. C., Sander, B., Sonnevi, K., Andersson, P. O., Jerkeman, M. & Smedby, K. E., 2022, I: British Journal of Haematology. 198, 2 , s. 267-277

Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission

Ekberg, S., Crowther, M., Harrysson, S., Jerkeman, M., E. Smedby, K. & Eloranta, S., 2022, I: British Journal of Cancer. 127, 9 , s. 1642-1649

Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Lindberg, Å., Eskelund, C. W., Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Geisler, C. H. & Jerkeman, M., 2022, I: Hematological Oncology. 40, 1, s. 23-31

Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma

Lokhande, L., Kuci Emruli, V., Eskelund, C. W., Kolstad, A., Hutchings, M., Räty, R., Niemann, C. U., Grønbæk, K., Jerkeman, M. & Ek, S., 2022, I: Cancer Reports. 5, 7

Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017

Albertsson Lindblad, A., Palsdottir, T., Smedby, K. E., Weibull, C. E., Glimelius, I. & Jerkeman, M., 2022, I: Haematologica. 107, 3, s. 740-743

The EHA Research Roadmap: Malignant Lymphoid Diseases

Dreyling, M., Jerkeman, M., Salles, G. & et al., 2022, I: HemaSphere. 6, 6, s. E726

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M., Kahl, B., Jerkeman, M., Kharfan-Dabaja, M. A., Locke, F. L., Shadman, M., Hill, B. T., Ahmed, S., Herrera, A. F., Sauter, C. S., Bachanova, V., Ghosh, N., Lunning, M., Kenkre, V. P. & Aljurf, M. och 14 andra, Wang, M., Maddocks, K. J., Leonard, J. P., Kamdar, M., Phillips, T., Cashen, A. F., Inwards, D. J., Sureda, A., Cohen, J. B., Smith, S. M., Carlo-Stella, C., Savani, B., Robinson, S. P. & Fenske, T. S., 2021 sep. 1, I: Transplantation and cellular therapy. 27, 9, s. 720-728 9 s.

How should we use ibrutinib in patients with mantle cell lymphoma?

Jerkeman, M., 2021 maj 1, I: British Journal of Haematology. 193, 3, s. 445-446 2 s.

Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors

Rodrigues, J. M., Nikkarinen, A., Hollander, P., Weibull, C. E., Räty, R., Kolstad, A., Amini, R. M., Porwit, A., Jerkeman, M., Ek, S. & Glimelius, I., 2021 maj 1, I: British Journal of Haematology. 193, 3, s. 520-531 12 s.

Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis

Saberi Hosnijeh, F., Casabonne, D., Nieters, A., Solans, M., Naudin, S., Ferrari, P., McKay, J. D., Benavente, Y., Weiderpass, E., Freisling, H., Severi, G., Boutron Ruault, M. C., Besson, C., Agnoli, C., Masala, G., Sacerdote, C., Tumino, R., Huerta, J. M., Amiano, P. & Rodriguez-Barranco, M. och 15 andra, Bonet, C., Barricarte, A., Christakoudi, S., Knuppel, A., Bueno-de-Mesquita, B., Schulze, M. B., Kaaks, R., Canzian, F., Späth, F., Jerkeman, M., Rylander, C., Tjønneland, A., Olsen, A., Borch, K. B. & Vermeulen, R., 2021, I: International Journal of Cancer. 148, 9, s. 2115-2128

ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Munshi, P. N., Hamadani, M., Kumar, A., Dreger, P., Friedberg, J. W., Dreyling, M., Kahl, B., Jerkeman, M., Kharfan-Dabaja, M. A., Locke, F. L., Shadman, M., Hill, B. T., Ahmed, S., Herrera, A. F., Sauter, C. S., Bachanova, V., Ghosh, N., Lunning, M., Kenkre, V. P. & Aljurf, M. och 14 andra, Wang, M., Maddocks, K. J., Leonard, J. P., Kamdar, M., Phillips, T., Cashen, A. F., Inwards, D. J., Sureda, A., Cohen, J. B., Smith, S. M., Carlo-Stella, C., Savani, B., Robinson, S. P. & Fenske, T. S., 2021, I: Bone Marrow Transplantation. 56, 12, s. 2911-2921

Clinical characteristics and histopathological patterns of hodgkin lymphoma and treatment outcomes at a tertiary cancer center in ethiopia

Adam, M., Bekueretsion, Y., Abubeker, A., Tadesse, F., Kwiecinska, A., Howe, R., Petros, B., Jerkeman, M. & Gebremedhin, A., 2021, I: JCO Global Oncology. 7, s. 277-288 12 s.

Detailed Long-Term Follow-Up of Patients Who Relapsed after the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3 Eskelund, C. W., Dimopoulos, K., Kolstad, A., Glimelius, I., Räty, R., Gjerdrum, L. M. R., Sonnevi, K., Josefsson, P., Nilsson-Ehle, H., Bentzen, H. H. N., Fagerli, U. M., Kuittinen, O., Haaber, J., Niemann, C. U., Pedersen, L. B., Larsen, M. T., Geisler, C. H., Hutchings, M., Jerkeman, M. & Grønbæk, K., 2021, I: HemaSphere. 5, 1, e510.

Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma

Jakobsen, L. H., Callréus, T., Sessa, M., Jerkeman, M., Andersen, M. & El-Galaly, T. C., 2021, I: Pharmacoepidemiology and Drug Safety.

EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic
Dreyling, M., Aurer, I., Federico, M., Jerkeman, M., Kersten, M. J., Linton, K., Mey, U., Tilly, H. & Buske, C., 2021, I: HemaSphere. 5, 2, s. e529

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden

Harrysson, S., Eloranta, S., Ekberg, S., Enblad, G., Jerkeman, M., Wahlin, B. E., Andersson, P. O. & Smedby, K. E., 2021 , I: Blood Cancer Journal. 11, 1, 9.

Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study

Ekberg, S., Harrysson, S., Jernberg, T., Szummer, K., Andersson, P. O., Jerkeman, M., Smedby, K. E. & Eloranta, S., 2021, I: Journal of Internal Medicine. 290, 5, s. 1048-1060

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dreyling, M., Ghielmini, M., Rule, S., Salles, G., Ladetto, M., Tonino, S. H., Herfarth, K., Seymour, J. F., Jerkeman, M. & ESMO Guidelines Committee, 2021, I: Annals of oncology : official journal of the European Society for Medical Oncology. 32, 3, s. 298-308 11 s.

Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets

Rodrigues, J. M., Porwit, A., Hassan, M., Ek, S. & Jerkeman, M., 2021, I: Leukemia and Lymphoma. 62, 11, s. 2637-2647 11 s.

Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival

Glimelius, I., Smedby, K. E., Albertsson-Lindblad, A., Crowther, M. J., Eloranta, S., Jerkeman, M. & Weibull, C. E., 2021, I: Blood Advances. 5, 6, s. 1638-1647 10 s.

p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma

Rodrigues, J. M., Hassan, M., Freiburghaus, C., Eskelund, C. W., Geisler, C., Räty, R., Kolstad, A., Sundström, C., Glimelius, I., Grønbæk, K., Kwiecinska, A., Porwit, A., Jerkeman, M. & Ek, S., 2020 dec., I: British Journal of Haematology. 191, 5, s. 796-805 10 s.

Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study

Naudin, S., Solans Margalef, M., Saberi Hosnijeh, F., Nieters, A., Kyrø, C., Tjønneland, A., Dahm, C. C., Overvad, K., Mahamat-Saleh, Y., Besson, C., Boutron-Ruault, M. C., Kühn, T., Canzian, F., Schulze, M. B., Peppa, E., Karakatsani, A., Trichopoulou, A., Sieri, S., Masala, G. & Panico, S. och 21 andra, Tumino, R., Ricceri, F., Chen, S. L. F., Barroso, L. L., Huerta, J. M., Sánchez, M. J., Ardanaz, E., Menéndez, V., Amiano Exezarreta, P., Spaeth, F., Jerkeman, M., Jirstrom, K., Schmidt, J. A., Aune, D., Weiderpass, E., Riboli, E., Vermeulen, R., Casabonne, D., Gunter, M., Brennan, P. & Ferrari, P., 2020 sep. 15, I: International Journal of Cancer. 147, 6, s. 1649-1656 8 s.

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma

Wästerlid, T., Harrysson, S., Andersson, T. M. L., Ekberg, S., Enblad, G., Andersson, P. O., Jerkeman, M., Eloranta, S. & Smedby, K. E., 2020 juli, I: American Journal of Hematology. 95, 7, s. 740-748 9 s.

Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study

Ekberg, S., E. Smedby, K., Glimelius, I., Nilsson-Ehle, H., Goldkuhl, C., Lewerin, C., Jerkeman, M. & Eloranta, S., 2020 juni, I: British Journal of Haematology. 189, 6, s. 1083-1092 10 s.

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Eskelund, C. W., Husby, S., Favero, F., Klausen, T. W., Rodriguez-Gonzalez, F. G., Kolstad, A., Pedersen, L. B., Räty, R. K., Geisler, C. H., Jerkeman, M., Weischenfeldt, J. & Grønbæk, K., 2020 maj 28, I: Blood. 135, 22, s. 2000-2004 5 s.

Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women

Mekuria, S., Jerkeman, M., Forslund, O., Fikru, S. & Borgfeldt, C., 2020 mars, I: Anticancer research. 40, 3, s. 1513-1517

Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

Solans, M., Benavente, Y., Saez, M., Agudo, A., Jakszyn, P., Naudin, S., Hosnijeh, F. S., Gunter, M., Huybrechts, I., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Sánchez, M. J., Amiano, P. & Chirlaque, M. D. och 26 andra, Ardanaz, E., Schmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Karakatsani, A., Valanou, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Mattiello, A., Skeie, G., Weiderpass, E., Jerkeman, M., Dias, J. A., Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Petersen, K. E. N., Tjønneland, A., de Sanjose, S., Vermeulen, R., Nieters, A. & Casabonne, D., 2020 mars, I: European Journal of Nutrition. 59, 2, s. 813-823 11 s.

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement

Sunderland, A. J., Steiner, R. E., Al Zahrani, M., Pinnix, C. C., Dabaja, B. S., Gunther, J. R., Nastoupil, L. J., Jerkeman, M., Joske, D., Cull, G., El-Galaly, T., Villa, D. & Cheah, C. Y., 2020, I: Cancer Medicine. 9, 2, s. 663-670 8 s.

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

Lokhande, L., Kuci Emruli, V., Kolstad, A., Hutchings, M., Räty, R., Jerkeman, M. & Ek, S., 2020, I: BMC Cancer. 20, 1, 1202.

National e-library for standardized chemotherapy regimens

Fyhr, A., Borell, J., Jerkeman, M. & Ek, Å., 2020, I: Acta Oncologica. 59, 9, s. 1079-1083 5 s.

Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study

Glimelius, I., Smedby, K. E., Eloranta, S., Jerkeman, M. & Weibull, C. E., 2019 nov. 13, I: British Journal of Haematology.

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Albertsson-Lindblad, A., Freiburghaus, C., Jerkeman, M. & Ek, S., 2019 aug. 6, I: Experimental Hematology and Oncology. 8, 1, 16.

Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

Bicler, J. L., Glimelius, I., Eloranta, S., Smeland, K. B., Brown, P. D. N., Jakobsen, L. H., Frederiksen, H., Jerkeman, M., Fosså, A., Andersson, T. M. L., Holte, H., Bøgsted, M., El-Galaly, T. C. & Smedby, K. E., 2019 mars 20, I: Journal of Clinical Oncology. 37, 9, s. 703-713 11 s.

Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

Solans, M., Benavente, Y., Saez, M., Agudo, A., Naudin, S., Hosnijeh, F. S., Noh, H., Freisling, H., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Rodríguez-Barranco, M., Amiano, P., Huerta, J. M. & Barricarte, A. och 26 andra, Schmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Bamia, C., Peppa, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Panico, S., Skeie, G., Weiderpass, E., Jerkeman, M., Ericson, U., Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Bolvig, A. K., Tjønneland, A., de Sanjose, S., Buckland, G., Vermeulen, R., Nieters, A. & Casabonne, D., 2019, I: International Journal of Cancer. 145, 1, s. 122-131

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

Ellin, F., Maurer, M. J., Srour, L., Farooq, U., Jerkeman, M., Connors, J. M., Smedby, K. E., Bennani, N. N., Ansell, S. M., Slack, G. W., Cerhan, J. R., Relander, T., Feldman, A. L. & Savage, K. J., 2019, I: British Journal of Haematology. 186, 3, s. e24-e27

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

Matasar, M. J., Luminari, S., Barr, P. M., Barta, S. K., Danilov, A. V., Hill, B. T., Phillips, T. J., Jerkeman, M., Magagnoli, M., Nastoupil, L. J., Persky, D. O. & Okosun, J., 2019, I: The Oncologist. 24, 11, s. e1236-e1250

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study

Wästerlid, T., Mohammadi, M., Smedby, K. E., Glimelius, I., Jerkeman, M., Bottai, M. & Eloranta, S., 2019, I: Journal of Internal Medicine. 285, 4, s. 455-468

Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?

Albertsson-Lindblad, A. & Jerkeman, M., 2019, I: Annals of Lymphoma. 3, 2, s. 1-15

Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

Callréus, T., El-Galaly, T. C., Jerkeman, M., de Nully Brown, P. & Andersen, M., 2019, I: Pharmaceutical Medicine. 33, 2, s. 83-88 6 s.

Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition

Costas, L., Lujan-Barroso, L., Benavente, Y., Allen, N. E., Amiano, P., Ardanaz, E., Besson, C., Boeing, H., Bueno-de-Mesquita, B., Cervenka, I., Fortner, R. T., Fournier, A., Gunter, M., Harlid, S., Huerta, J. M., Jerkeman, M., Jirström, K., Kaaks, R., Karakatsani, A. & Khaw, K. T. och 22 andra, Kotanidou, A., Lund, E., Masala, G., Mattiello, A., Melin, B., Menéndez, V., Murphy, N., Nieters, A., Overvad, K., Riboli, E., Sacerdote, C., Sánchez, M. J., Schmidt, J. A., Sieri, S., Tjønneland, A., Trichopoulou, A., Tumino, R., Vermeulen, R., Weiderpass, E., de Sanjosé, S., Agudo, A. & Casabonne, D., 2019, I: American Journal of Epidemiology. 188, 2, s. 274-281 8 s.

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia

Ljungars, A., Mårtensson, L., Mattsson, J., Kovacek, M., Sundberg, A., Tornberg, U.-C., Jansson, B., Persson, N., Emruli, V. K., Ek, S., Jerkeman, M., Hansson, M., Juliusson, G., Ohlin, M., Frendéus, B., Teige, I. & Mattsson, M., 2018 dec. 1, I: JCO Precision Oncology. 2, 1

Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of followup

Hagström, H., Andreasson, A., Carlsson, A. C., Jerkeman, M. & Carlsten, M., 2018 aug. 23, I: PLoS ONE. 13, 8, e0202651.

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Ekberg, S., Jerkeman, M., Andersson, P. O., Enblad, G., Wahlin, B. E., Hasselblom, S., Andersson, T. M., Eloranta, S. & Smedby, K. E., 2018 aug. 1, I: American Journal of Hematology. 93, 8, s. 1020-1028 9 s.

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Rule, S., Jurczak, W., Jerkeman, M., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S. G., Thieblemont, C., Zhou, W., Henninger, T., Goldberg, J., Vermeulen, J. & Dreyling, M., 2018 aug., I: Leukemia. 32, 8, s. 1799-1803

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

Drott, K., Hagberg, H., Papworth, K., Relander, T. & Jerkeman, M., 2018 juni 26, I: Blood Advances. 2, 12, s. 1386-1392 7 s.

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF- κ B activity

Freiburghaus, C., Emruli, V. K., Johansson, A., Eskelund, C. W., Grønbæk, K., Olsson, R., Ek, F., Jerkeman, M. & Ek, S., 2018 apr. 25, I: BMC Cancer. 18, 1, 466.

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): A multicentre, open-label, single-arm, phase 2 trial

Jerkeman, M., Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., Kuitunen, H., Geisler, C. H., Grønbæk, K. & Kolstad, A., 2018 mars, I: The Lancet Haematology. 5, 3, s. e109-e116

Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: A critical assessment of the R-IPI, IPI, and NCCN-IPI
Bicler, J., Eloranta, S., de Nully Brown, P., Frederiksen, H., Jerkeman, M., Smedby, K. E., Bøgsted, M. & El-Galaly, T. C., 2018 jan., I: *Cancer Medicine*. 7, 1, s. 114-122

Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study
Ellin, F., Jerkeman, M., Törnqvist, J., Brudin, L. & Relander, T., 2018, I: *Hematological Oncology*. 36, 1, s. 159-165

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Eskelund, C. W., Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Pedersen, L. B., Geisler, C. H., Jerkeman, M. & Grønbæk, K., 2018, I: *Haematologica*. 103, 11, s. e541-e543

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Dang, N. H., Ogura, M., Castaigne, S., Fayad, L. E., Jerkeman, M., Radford, J., Pezzutto, A., Bondarenko, I. N., Stewart, D. A., Shnайдман, M., Sullivan, S., Vandendries, E., Tobinai, K., Ramchandren, R., Hamlin, P. A., Giné, E. & Ando, K., 2018, I: *British Journal of Haematology*. 182, 4, s. 583-586

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

Dreyling, M., Aurer, I., Cortelazzo, S., Hermine, O., Hess, G., Jerkeman, M., Le Gouill, S., Ribrag, V., Trněný, M., Visco, C., Walewski, J., Zaja, F. & Zinzani, P. L., 2018, I: *Leukemia and Lymphoma*. 59, 8, s. 1814-1828

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

Maurer, M. J., Ellin, F., Srour, L., Jerkeman, M., Bennani, N. N., Connors, J. M., Slack, G. W., Smedby, K. E., Ansell, S. M., Link, B. K., Cerhan, J. R., Relander, T., Savage, K. J. & Feldman, A. L., 2017 dec. 20, I: *Journal of Clinical Oncology*. 35, 36, s. 4019-4026 8 s.

Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

Cederleuf, H., Hjort Jakobsen, L., Ellin, F., de Nully Brown, P., Stauffer Larsen, T., Bøgsted, M., Relander, T., Jerkeman, M. & El-Galaly, T. C., 2017 dec. 2, I: *Leukemia and Lymphoma*. 58, 12, s. 2815-2823 9 s.

Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

Karvonen, H., Chiron, D., Niininen, W., Ek, S., Jerkeman, M., Moradi, E., Nykter, M., Heckman, C. A., Kallioniemi, O., Murumägi , A. & Ungureanu, D., 2017 nov. 9, I: *Blood Advances*. 1, 24, s. 2257-2268

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., Pedersen, A., Niemann, C., Raty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldberg, P., Jerkeman, M. & Grønbæk, K., 2017 okt. 26, I: *Blood*. 130, 17, s. 1903-1910 8 s.

Frequency and clinical implications of SOX11 expression in Burkitt lymphoma

Wästerlid, T., Nordström, L., Freiburghaus, C., Pedersen, M., Nørgaard, P., Gang, A. O., Brown, P., Dictor, M., Jerkeman, M. & Ek, S., 2017, I: *Leukemia & Lymphoma*. 58, 7, s. 1760-1763 4 s.

Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

Hess, G., Rule, S., Jurczak, W., Jerkeman, M., Santucci Silva, R., Rusconi, C., Caballero, D., Joao, C., Witzens-Harig, M., Bence-Bruckler, I., Cho, S.-G., Zhou, W., Goldberg, J. D., Trambitas, C., Enny, C., Vermeulen, J., Traina, S., Chiou, C. F., Diels, J. & Dreyling, M., 2017, I: *Leukemia and Lymphoma*. 58, 12, s. 2824-2832

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Kolstad, A., Pedersen, L. B., Eskelund, C. W., Husby, S., Grønbæk, K., Jerkeman, M., Laurell, A., Räty, R., Elonen, E., Andersen, N. S., Brown, P. D. N., Kimby, E., Bentzen, H., Sundström, C., Ehinger, M., Karjalainen-Lindsberg, M.-L., Delabie, J., Ralfkiaer, E., Fagerli, U.-M. & Nilsson-Ehle, H. och 4 andra, Lauritszen, G. F., Kuittinen, O., Niemann, C. &

Geisler, C. H., 2017, I: *Biology of Blood and Marrow Transplantation*. 23, 3, s. 428-435

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., Ladetto, M. & on behalf of the ESMO Guidelines Committee, 2017, I: *Annals of Oncology*. 28, s. iv62-iv71

Targeting of B-cell receptor signalling in B-cell malignancies

Jerkeman, M., Hallek, M., Dreyling, M., Thieblemont, C., Kimby, E. & Staudt, L., 2017, I: *Journal of Internal Medicine*. 282, 5, s. 415-428

The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study

Cederleuf, H., Bjerregård Pedersen, M., Jerkeman, M., Relander, T., d'Amore, F. & Ellin, F., 2017, I: *British Journal of Haematology*. 178, 5, s. 739-746

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study

Pauly, F., Fjordén, K., Leppä, S., Holte, H., Björkholm, M., Fluge, Møller Pedersen, L., Eriksson, M., Isinger-Ekstrand, A., Borrebaeck, C. A. K., Jerkeman, M. & Wingren, C., 2016 nov. 18, I: *Blood Cancer Journal*. 6, 11, s. e501

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

Melén, C. M., Enblad, G., Sonnevi, K., Junlén, H. R., Smedby, K. E., Jerkeman, M. & Wahlin, B. E., 2016 nov. 1, I: *British Journal of Haematology*. 175, 4, s. 614-622 9 s.

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

Cheah, C. Y., Bröckelmann, P. J., Chihara, D., Moskowitz, A. J., Engert, A., Jerkeman, M., El-Galaly, T. C., Augustson, B., Vose, J., Bartlett, N. L., Villa, D., Connors, J. M., Feldman, T., Pinnix, C. C., Milgrom, S. A., Dabaja, B., Oki, Y. & Fanafe, M. A., 2016 sep. 1, I: *American Journal of Hematology*. 91, 9, s. 894-899 6 s.

Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

Albertsson-Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiaer, E., Karjalainen-Lindsberg, M.-L., Sundström, C., Ehinger, M., Geisler, C. & Jerkeman, M., 2016 juni 27, I: *Blood*. 128, 14, s. 1814-1820

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau

Eskelund, C. W., Kolstad, A., Jerkeman, M., Räty, R., Laurell, A., Eloranta, S., Smedby, K. E., Husby, S., Pedersen, L. B., Andersen, N. S., Eriksson, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritszen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundström, C. & Delabie, J. och 7 andra, Karjalainen-Lindsberg, M. L., Workman, C. T., Garde, C., Elonen, E., Brown, P., Grønbæk, K. & Geisler, C. H., 2016, I: *British Journal of Haematology*. 175, 3, s. 410-418

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Haarig, M., Hess, G., Bence-Bruckler, I., Cho, S.-G., Bothos, J., Goldberg, J. D., Enny, C., Traina, S., Balasubramanian, S., Bandyopadhyay, N. & Sun, S. och 3 andra, Vermeulen, J., Rizo, A. & Rule, S., 2016, I: *The Lancet*. 387, 10020, s. 770-778

No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Linderoth, J., Mylam, K. J., Molin, D., Johnsen, H. E., Bøgsted, M., Jerkeman, M. & El-Galaly, T. C., 2016, I: *British Journal of Haematology*.

Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.

SZENTKIRALYI SZEKELY, E., Lindén, O., Peterson, S. & Jerkeman, M., 2016, I: European Journal of Haematology. 97, 4 , s. 393–398

Antagonistic Human Fc γ RIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.

Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., Mattson, J., Sundberg, A., Vaughan, A. T., Shah, V., Smyth, N. R., Sheth, B., Chan, H. T. C., Li, Z.-C., Williams, E. L., Manfredi, G., Oldham, R. J., Mockridge, C. I., James, S. A. & Dahal, L. N. och 12 andra, Hussain, K., Nilsson, B., Verbeek, J. S., Juliusson, G., Hansson, M., Jerkeman, M., Johnson, P. W. M., Davies, A., Beers, S. A., Glennie, M. J., Frendéus, B. & Cragg, M. S., 2015, I: Cancer Cell. 27, 4, s. 473-488

Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.

Ellin, F., Landström, J., Jerkeman, M. & Relander, T., 2015, I: Blood. 126, 1, s. 36-41

Emerging role of SOX11 in mantle cell lymphoma

Kuci, V., Nordström, L., Jerkeman, M. & Ek, S., 2015, I: Blood and Lymphatic Cancer: Targets and Therapy. 5, s. 35-41

Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.

Wästerlid, T., Werner Hartman, L., Szekely, E. & Jerkeman, M., 2015, I: Hematological Oncology.

Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.

Jerkeman, M. & Lindén, O., 2015, I: European Journal of Haematology.

Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 - trends in cure proportions by clinical characteristics.

Glimelius, I., Ekberg, S., Jerkeman, M., Chang, E. T., Björkholm, M., Andersson, T. M. L., Smedby, K. E. & Eloranta, S., 2015, I: American Journal of Hematology. 90, 12, s. 1128-1134

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer.

Olofsson, S.-E., Nodin, B., Gaber, A., Eberhard, J., Uhlén, M., Jirström, K. & Jerkeman, M., 2015, I: PLoS ONE. 10, 3, e0121300.

Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study

Hedstrom, G., Peterson, S., Berglund, M., Jerkeman, M. & Enblad, G., 2015, I: Acta Oncologica. 54, 6, s. 924-932

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.

Husby, S., Ralfkiaer, U., Garde, C., Zandi, R., Ek, S., Kolstad, A., Jerkeman, M., Laurell, A., Räty, R., Pedersen, L. B., Pedersen, A., Ehinger, M., Sundström, C., Karjalainen-Lindsberg, M.-L., Delabie, J., Clasen-Linde, E., Brown, P., Cowland, J., Workman, C. T. & Geisler, C. H. och 1 andra, Grønbæk, K., 2015, I: Blood. 125, 17, s. 2669-2677

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Kofoed Damm, J., Gordon, S., Ehinger, M., Jerkeman, M., Gullberg, U., Hultquist, A. & Drott, K., 2015, I: Experimental hematology & oncology. 4, 4

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

El-Galaly, T. C., Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Nilsson-Ehle, H., Szekely, E., Mylam, K. J., Hjalmar, V., Johnsen, H. E., Bøgsted, M. & Jerkeman, M., 2015, I: Journal of Clinical Oncology. 33, 34, s. 3993-3998

Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment
Nord, C., Olofsson, S.-E., Glimelius, I., Cederman, G. C., Ekberg, S., Cavallin-Ståhl, E., Neovius, M., Jerkeman, M. & Smedby, K. E., 2015, I: Acta Oncologica. 54, 10, s. 1770-1780

Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
Glimelius, I., Ekberg, S., Linderoth, J., Jerkeman, M., Chang, E. T., Neovius, M. & Smedby, K. E., 2015, I: Journal of Cancer Survivorship. 9, 4, s. 599-609

The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
Hedstrom, G., Hagberg, O., Jerkeman, M. & Enblad, G., 2015, I: Acta Oncologica. 54, 6, s. 916-923

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials.
Hoster, E., Geisler, C. H., Doorduijn, J., van der Holt, B., Walewski, J., Bloehdorn, J., Ribrag, V., Salles, G., Hallek, M., Pott, C., Szymczyk, M., Kolstad, A., Laurell, A., Räty, R., Jerkeman, M., Van't Veer, M., Kluin-Nelemans, J. C., Klapper, W., Unterhalt, M. & Dreyling, M. och 1 andra, Hermine, O., 2015, I: Leukemia.

Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
Dreyling, M., Amador, V., Callanan, M., Jerkeman, M., Le Gou, S., Pott, C., Rule, S. & Zaja, F., 2015, I: Leukemia & Lymphoma. 56, 4, s. 866-876

Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.

Taskinen, M., Louhimo, R., Koivula, S., Chen, P., Rantanen, V., Holte, H., Delabie, J., Karjalainen-Lindsberg, M.-L., Björkholm, M., Fluge, O., Pedersen, L. M., Fjordén, K., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppä, S., 2014, I: PLoS ONE. 9, 3, e91031.

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
Laurell, A., Kolstad, A., Jerkeman, M., Raty, R. & Geisler, C. H., 2014, I: Leukemia & Lymphoma. 55, 5, s. 1206-1208

Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.

Pauly, F., Smedby, K. E., Jerkeman, M., Hjalgrim, H., Ohlsson, M., Rosenquist, R., Borrebaeck, C. A. K. & Wingren, C., 2014, I: Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis. 38, 6, s. 682-690

Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study
Szekely, E., Hagberg, O., Arnljots, K. & Jerkeman, M., 2014, I: Leukemia & Lymphoma. 55, 8, s. 1838-1843

Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., Bogsrud, T. V., Kimby, E., Hansen, P. B., Fagerli, U.-M., Nilsson-Ehle, H., Lauritsen, G. F., Lehmann, A. K., Sundstrom, C., Karjalainen-Lindsberg, M.-L., Ralfkiaer, E., Ehinger, M. & Delabie, J. och 6 andra, Bentzen, H., Schildt, J., Kostova-Aherdan, K., Frederiksen, H., Brown, P. D. N. & Geisler, C. H., 2014, I: Blood. 123, 19, s. 2953-2959

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Abrahamsson, A., Albertsson Lindblad, A., Brown, P. N., Baumgartner-Wennerholm, S., Pedersen, L. M., D'Amore, F., Nilsson-Ehle, H., Jensen, P., Pedersen, M., Geisler, C. H. & Jerkeman, M., 2014, I: Blood. 124, 8, s. 1288-1295

Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Ellin, F., Landström, J., Jerkeman, M. & Relander, T., 2014, I: Blood. 124, 10, s. 1570-1577

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.

Nordström, L., Sernbo, S., Eden, P., Grønbaek, K., Kolstad, A., Räty, R., Karjalainen, M.-L., Geisler, C., Ralfkiaer, E., Sundström, C., Laurell, A., Delabie, J., Ehinger, M., Jerkeman, M. & Ek, S., 2014, I: British Journal of Haematology. 166, 1 , s. 98-108

Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry

Ellin, F., Jerkeman, M., Hagberg, H. & Relander, T., 2014, I: Acta Oncologica. 53, 7, s. 927-934

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study

Holte, H., Leppa, S., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M.-L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstrom, M., Janes, R., Pedersen, L. M., Anderson, H., Jerkeman, M. & Eriksson, M., 2013, I: Annals of Oncology. 24, 5, s. 1385-1392

Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.

Wästerlid, T., Brown, P. N., Hagberg, O., Hagberg, H., Pedersen, L. M., D'Amore, F. & Jerkeman, M., 2013, I: Annals of Oncology. 24, 7, s. 1879-1886

Expanded clinical and experimental use of SOX11-using a monoclonal antibody

Nordström, L., Andreasson, U., Jerkeman, M., Dictor, M., Borrebaeck, C. & Ek, S., 2012, I: BMC Cancer. 12, 269

Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma

Fjordén, K., Joost, P., Ehinger, M., Edén, P., Jerkeman, M., Cavallin-Ståhl, E. & Linderöth, J., 2012, I: Leukemia & Lymphoma. 53, 9, s. 1764-1768

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

Riihijarvi, S., Nurmi, H., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. M., Fjordén, K., Jerkeman, M., Eriksson, M. & Leppa, S., 2012, I: European Journal of Haematology. 89, 5, s. 395-402

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Geisler, C. H., Kolstad, A., Laurell, A., Jerkeman, M., Raty, R., Andersen, N. S., Pedersen, L. B., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M.-L. & Brown, P. och 1 andra, Elonen, E., 2012, I: British Journal of Haematology. 158 , 3, s. 355-362

Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.

Ageberg, M., Fjordén, K., Lindén, O., Linderöth, J., Jerkeman, M. & Drott, K., 2011, I: Experimental Cell Research. 317, s. 1179-1191

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy

Riihijarvi, S., Taskinen, M., Jerkeman, M. & Leppa, S., 2011, I: European Journal of Haematology. 86, 2, s. 124-128

Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.

Abrahamsson, A., Dahle, N. & Jerkeman, M., 2011, I: Leukemia & Lymphoma. 52, 10, s. 1929-1935

Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time

Geisler, C. H., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H. E. N., Nilsson-Ehle, H., Kuittinen, O., Lauritsen, G. F., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-

Lindsberg, M.-L., Pedersen, L. B., Andersen, N. S. & Brown, P. D. N. och 1 andra, Elonen, E., 2011, I: *Biology of Blood and Marrow Transplantation*. 17, 2, s. 196-196

Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.

Wästerlid, T., Jonsson, B., Hagberg, H. & Jerkeman, M., 2011, I: *Leukemia & Lymphoma*. 52, 11, s. 2090-2096

Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.

Olofsson, S.-E., Tandstad, T., Jerkeman, M., Dahl, O., Ståhl, O., Klepp, O., Bremnes, R. M., Cohn-Cedermark, G., Langberg, C. W., Laurell, A., Solberg, A., Stierner, U., Wahlqvist, R., Wijkström, H., Anderson, H. & Cavallin-Ståhl, E., 2011, I: *Journal of Clinical Oncology*. 29, s. 2032-2039

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Fjordén, K., Linderoth, J., Nyman, H., Ehinger, M., Joost, P., Bendahl, P.-O., Leppä, S. & Jerkeman, M., 2010, I: *Leukemia & Lymphoma*. 51, s. 1643-1648

Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study

Koivula, S., Taskinen, M., Chen, P., Holte, H., Delabie, J., Lindsberg, M. L. K., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M., Hautaniemi, S. & Leppä, S., 2010, I: *Blood*. 116, 21, s. 1281-1281

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study

Riihuarvi, S., Nyman, H., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M. & Leppä, S., 2010, I: *Blood*. 116, 21, s. 1686-1686

Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.

Andreasson, U., Edén, P., Peterson, C., Högerkorp, C.-M., Jerkeman, M., Andersen, N., Berglund, M., Sundström, C., Rosenquist, R., Borrebaeck, C. & Ek, S., 2010, I: *American Journal of Hematology*. 85, 6, s. 418-425

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

d'Amore, F., Radford, J., Relander, T., Jerkeman, M., Tilly, H., Osterborg, A., Morschhauser, F., Gramatzki, M., Dreyling, M., Bang, B. & Hagberg, H., 2010, I: *British Journal of Haematology*. 150, 5, s. 565-573

Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

Riihijarvi, S., Koivula, S., Nyman, H., Fjordén, K., Jerkeman, M. & Leppä, S., 2010, I: *Modern Pathology*. 23, 5, s. 686-693

SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies

Gustavsson, E., Sernbo, S., Andersson, E., Brennan, D., Dictor, M., Jerkeman, M., Borrebaeck, C. & Ek, S., 2010, I: *Molecular Cancer*. 9, 187

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Geisler, C. H., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A. M., Nilsson-Ehle, H., Kuittinen, O., Lauritszen, G. F., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M.-L., Brown, P. & Elonen, E., 2010, I: *Blood*. 115, 8, s. 1530-1533

(90)y-Ibritumomab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

Kolstad, A., Laurell, A., Andersen, N. S., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., Bogsrød, T. V., Nordstrom, M., Gillstrom, D., Hansen, P. B., Bentzen, H., Fagerli, U.-M., Meyer, P., Nilsson-Ehle, H., Jerkeman, M., Lehmann, A. K., Lauritszen, G. F., Sundstrom, C. & Delabie, J. och 4 andra, Karjalainen-Lindsberg, M.-L., Ralfkiaer, E., Ehinger, M. & Geisler, C. H., 2009, I: *Blood*. 114, 22, s. 384-384

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M.-L., Banham, A. H., Enblad, G. & Leppa, S., 2009, I: European Journal of Haematology. 82, 5, s. 364-372

Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.

Andreasson, U., Dictor, M., Jerkeman, M., Berglund, M., Sundström, C., Linderoth, J., Rosenquist, R., Borrebaeck, C. & Ek, S., 2009, I: American Journal of Hematology. 84, s. 803-808

Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA

Olofsson, S., Dahl, O., Jerkeman, M., Cohn-Cedermark, G., Klepp, O., Stierner, U., Tornblom, M., Wahlqvist, R. & Cavallin-Ståhl, E., 2009, I: Journal of Clinical Oncology. 27, 15

Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma.

Andersen, N. S., Pedersen, L. B., Laurell, A., Elonen, E., Kolstad, A., Boesen, A. M., Pedersen, L. M., Lauritsen, G. F., Ekanger, R., Nilsson-Ehle, H., Nordström, M., Fredén, S., Jerkeman, M., Eriksson, M., Väärä, J., Malmer, B. & Geisler, C. H., 2009, I: Journal of Clinical Oncology. 27, s. 4365-4370

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M.-L., Banham, A. H. & Leppa, S., 2009, I: Modern Pathology. 22, 8, s. 1094-1101

B cell lymphomas express CX(3)CR1 a non-B cell lineage adhesion molecule.

Andreasson, U., Ek, S., Merz, H., Rosenquist, R., Andersen, N., Jerkeman, M., Dictor, M. & Borrebaeck, C. A. K., 2008, I: Cancer Letters. 259, 2, s. 138-145

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M., Banham, A., Enblad, G. & Leppa, S., 2008, I: Annals of Oncology. 19, Suppl. 4, s. iv 142-iv 142

Burkitt's lymphoma: Comparison of 2 nationwide population-based lymphoma registries

Brown, P. D., Samuelsson, V., d'Amore, F., Lindh, J., Hagberg, H., Nilsson, G., Bernell, P., Pedersen, L. M. & Jerkeman, M., 2008, I: Annals of Oncology. 19, Suppl. 4, s. iv 131-iv 131

Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.

Linderoth, J., Edén, P., Ehinger, M., Valcich, J., Jerkeman, M., Bendahl, P.-O., Berglund, M., Enblad, G., Erlanson, M., Roos, G. & Cavallin-Ståhl, E., 2008, I: British Journal of Haematology. 141, 4, s. 423-432

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A. M., Kuittinen, O., Lauritsen, G. F., Nilsson-Ehle, H., Ralfkiaer, E., Åkerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J. & Karjalainen-Lindsberg, M.-L. och 2 andra, Brown, P. & Elonen, E., 2008, I: Blood. 112, 7, s. 2687-2693

Nuclear expression of the Non-B Cell Lineage Sox11 Transcription Factor Identifies Mantle Cell Lymphoma

Ek, S., Dictor, M., Jerkeman, M., Jirström, K. & Borrebaeck, C., 2008, I: Blood. 111, 2, s. 800-805

R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.

Holte, H., Leppa, S. M., Bjorkholm, M., Fluge, O., Jyrkkio, S., Delabie, J., Sundstrom, C., Karjalainen-Lindsberg, M.-L., Erlanson, M., Kolstad, A., Fossa, A., Ostenstad, B., Lofvenberg, E., Nordstroem, M., Moller-Pedersen, L., Anderson, H., Jerkeman, M. & Eriksson, M., 2008, I: *Blood*. 112, 11, s. 1233-1233

Sox11, a non-B cell lineage transcription factor, is overexpressed in mantle cell lymphoma

Dictor, M., Ek, S., Jerkeman, M., Jirström, K. & Borrebaeck, C., 2008, I: *Annals of Oncology*. 19, Suppl. 4, s. iv 172-iv 173

Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression

Andreasson, U., Dictor, M., Jerkeman, M., Rosenquist, R., Borrebaeck, C. & Ek, S., 2008, I: *Annals of Oncology*. 19, Suppl. 4, s. iv 111-iv 111

Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers

Hansson, M., Jerkeman, M. & Dictor, M., 2007, I: *European Journal of Haematology*. 79, 2, s. 159-165

CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma.

Linderoth, J., Ehinger, M., Jerkeman, M., Bendahl, P.-O., Åkerman, M., Berglund, M., Enblad, G., Erlanson, M., Roos, G. & Cavallin-Ståhl, E., 2007, I: *Leukemia & Lymphoma*. 48, 9, s. 1774-1779

Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN

Fridberg, M., Servin, A., Anagnostaki, L., Linderoth, J., Berglund, M., Soderberg, O., Enblad, G., Rosen, A., Mustelin, T., Jerkeman, M., Persson, J. L. & Gjörlöff Wingren, A., 2007, I: *Leukemia & Lymphoma*. 48, 11, s. 2221-2232

Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.

Linderoth, J., Ehinger, M., Åkerman, M., Cavallin-Ståhl, E., Enblad, G., Erlanson, M. & Jerkeman, M., 2007, I: *European Journal of Haematology*. 79, 2, s. 146-149

Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy

Engleson, J., Soller, M., Panagopoulos, I., Dahlen, A., Dictor, M. & Jerkeman, M., 2006, I: *BMC Cancer*. 6

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

Berglund, M., Thunberg, U., Amini, R., Book, M., Roos, G., Erlanson, M., Linderoth, J., Dictor, M., Jerkeman, M., Cavallin-Ståhl, E., Sundstrom, C., Rehn-Eriksson, S., Backlin, C., Hagberg, H., Rosenquist, R. & Enblad, G., 2005, I: *Modern Pathology*. 18, 8, s. 1113-1120

High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma

Bjorck, E., Ek, S., Landgren, O., Jerkeman, M., Ehinger, M., Bjorkholm, M., Borrebaeck, C., Porwit-MacDonald, A. & Nordenskjold, M., 2005, I: *Blood*. 105, 7, s. 2908-2915

Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.

Jerkeman, M., Anderson, H., Dictor, M., Kvaløy, S., Åkerman, M. & Cavallin-Ståhl, E., 2004, I: *Annals of Hematology*. 83, 7, s. 414-419

ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.

Jerkeman, M., Leppä, S., Kvaløy, S. & Holte, H., 2004, I: *European Journal of Haematology*. 73, 3, s. 179-182

Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study.

Linderoth, J., Jerkeman, M., Cavallin-Ståhl, E., Kvaløy, S. & Torlakovic, E., 2003, I: *Clinical Cancer Research*. 9, 2, s. 722-728

Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study.

Jerkeman, M., Aman, P., Cavallin-Ståhl, E., Torlakovic, E., Åkerman, M., Mitelman, F. & Fioretos, T., 2002, I: International Journal of Oncology. 20, 1, s. 161-165

Expression of the B-cell transcription factor PU.1 is strongly correlated with CD10, CD79a, CD20, CD22, and bcl-6 expression in diffuse large B-cell lymphoma (DLBCL)

Torlakovic, E., Linderoth, J., Jerkeman, M., Kvaloy, S. & Delabie, J., 2001, I: Blood. 98, 11, s. 330A-330A

Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial

Jerkeman, M., Kaasa, S., Hjermstad, M., Kvaloy, S. & Cavallin-Ståhl, E., 2001, I: Medical Oncology. 18, 1, s. 85-94

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP

Messori, A., Vaiani, M., Trippoli, S., Rigacci, L., Jerkeman, M. & Longo, G., 2001, I: British Journal of Cancer. 84, 3, s. 303-307

Aggressive lymphoma

Jerkeman, M., 2000, Department of Oncology, Clinical Sciences, Lund University. 149 s.

Residual mass in aggressive lymphoma--does size, measured by computed tomography, influence clinical outcome?

Rodriguez-Catarino, M., Jerkeman, M., Ahlstrom, H., Glimelius, B. & Hagberg, H., 2000, I: Acta Oncologica. 39, 4, s. 485-489

CHOP versus MACOP-B in aggressive lymphoma—a Nordic Lymphoma Group randomised trial

Jerkeman, M., Anderson, H., Cavallin-Ståhl, E., Dictor, M., Hagberg, H., Johnson, A., Kaasa, S., Kvaloy, S., Sundstrom, C. & Åkerman, M., 1999, I: Annals of Oncology. 10, 9, s. 1079-1086

Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas

Jerkeman, M., Johansson, B., Åkerman, M., Cavallin-Ståhl, E., Kristoffersson, U. & Mitelman, F., 1999, I: European Journal of Haematology. 62, 3, s. 184-190

Bacteremic and non-bacteremic febrile urinary tract infection—a review of 168 hospital-treated patients

Jerkeman, M. & Braconier, J. H., 1992, I: Infection. 20, 3, s. 143-145